Medical News

RSS

MEDecision earns NCQA Healthcare Effectiveness Data and Information Set Software Certification

MEDecision, Inc., a leading provider of collaborative healthcare management solutions, has earned the National Committee for Quality Assurance (NCQA) Healthcare Effectiveness Data and Information Set (HEDIS®) Software Certification for its programs that identify "care opportunities."

15 Nov 2010

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

15 Nov 2010

Dyadic third quarter total revenue decreases to $2.0 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

BioTime third quarter total revenues increase 82% to $815,284

BioTime, Inc. today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments.

15 Nov 2010

MedClean enters distribution agreement with SunBelt

MedClean Technologies, the leading provider of on-site technology for the treatment and disposal of medical waste and the destruction of confidential documents and related media, today announced it has signed a distribution agreement with SunBelt Medical Services, Inc. With this agreement, MedClean now has 11 regional distributors covering 41 states, one national partner targeting the Veteran's Administration, and one international partner covering Canada.

15 Nov 2010

RXi third quarter net loss increases to $4.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Electromed first quarter net revenues increase 29% to $4,165,000

Electromed, Inc. today announced financial results for the three months ended September 30, 2010. Net revenues for the three months ended September 30, 2010 were approximately $4,165,000, a 29% increase compared to net revenues of approximately $3,228,000 for the same period last year.

15 Nov 2010

Biostar third quarter net income increases 9.8% to $3.4 million

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Unilife and IMCO enter exclusive marketing program for Unitract range of 1mL safety syringes

Unilife Corporation today announced that it has commenced U.S. sales of its Unitract® range of 1mL safety syringes.

15 Nov 2010

PLC Systems third quarter net loss decrease to $5,000

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today reported financial results for the three- and nine-month periods ended September 30, 2010.

15 Nov 2010

PGxHealth presents results from studies using FAMILION genetic testing at 2010 AHA

Clinical Data, Inc., today announced that results of studies using its FAMILION® genetic testing were presented at the 2010 American Heart Association (AHA) meeting. PGxHealth, a division of Clinical Data, together with its collaborators, presented results from the largest, most comprehensive studies of genetic variation associated with certain cardiac conditions that were revealed using FAMILION testing.

15 Nov 2010

Weikang third quarter revenue increases 55.2% to record $17.4 million

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced record fiscal 2010 third quarter results for period ended September 30, 2010.

15 Nov 2010

StemCells seeks Swiss authorization to conduct human neural stem cells clinical trial in chronic spinal cord injury

StemCells, Inc. announced today that is has filed an application with Swissmedic, the Swiss regulatory agency for therapeutic products, to conduct a clinical trial in Switzerland of the Company's HuCNS-SC® purified human neural stem cells in chronic spinal cord injury patients. If authorized, the study would enroll patients who are three to 12 months post-injury.

15 Nov 2010

Protox decreases third quarter net and comprehensive loss to $1.6 million

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today released financial results for the third quarter, ended September 30, 2010.

15 Nov 2010

Autonomy introduces Meaning Based Healthcare platform

Autonomy Corporation plc, a global leader in infrastructure software for the enterprise, today announced the availability of the Autonomy Meaning Based Healthcare (MBH) platform, a comprehensive set of clinical diagnosis and information governance technologies designed to help Healthcare Delivery Organizations (HDOs) provide higher quality care at lower costs.

15 Nov 2010

Milestone Scientific third quarter total revenues increase to $1.93 million

Milestone Scientific Inc., the recognized leader in advanced, computer-controlled drug delivery technologies, announces its financial results for the third quarter and nine months ended September 30, 2010.

15 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

National Health third quarter revenues increase 12.3%

National Health Partners, Inc., a leading provider of unique discount healthcare membership programs, is pleased to announce today that the Company has achieved positive earnings for the quarter ended September 30, 2010 compared to a loss of $522,542 for the same period last year. Revenues for the 3rd quarter grew 12.3% over the same period last year.

15 Nov 2010

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides, Inc. reports that its optimized FluCide™ drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

15 Nov 2010

Endo announces private offering of $400 million senior unsecured notes

Endo Pharmaceuticals Holdings Inc. today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.

15 Nov 2010